2Seventy Bio Inc
NASDAQ:TSVT
Net Margin
2Seventy Bio Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
2Seventy Bio Inc
NASDAQ:TSVT
|
257.9m USD |
-151%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.4B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.4B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.2B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.8B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
56.6B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.2B USD |
-11%
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on 2Seventy Bio Inc's most recent financial statements, the company has Net Margin of -151.2%.
You don't have any saved screeners yet